MRVI Overview

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Wall Street analysts forecast MRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRVI is4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Maravai LifeSciences Holdings Inc revenue for the last quarter amounts to 49.87M USD, decreased -11.59

Maravai LifeSciences Holdings Inc. EPS for the last quarter amounts to -0.25 USD, increased 38.89

Maravai LifeSciences Holdings Inc (MRVI) has 435 emplpoyees as of March 03 2026.

Today MRVI has the market capitalization of 928.01M USD.